June 21, 2001 INNSBRUCK, Austria – Duke University Medical Center researchers reported Friday that specially encapsulated insulin-producing pancreas cells from pigs have kept a diabetic baboon from needing insulin for more than nine months. If this approach continues to show success in similar experimental models, the researchers believe that trials involving humans with insulin-dependant diabetes could begin within a year.
The researchers coated islet cells taken from pig pancreases with a complex carbohydrate known as alginate and injected the resulting spheres into the abdominal cavity of a diabetic baboon. The cells reacted properly to changing levels of glucose in the blood and secreted appropriate amounts of insulin to ensure normal glucose metabolism.
Insulin, a hormone produced and secreted by specialized pancreas cells called islets of Langerhans, converts sugars, starches and other foods into the energy needed for everyday life. These islets do not function properly in people with insulin-dependent, or Type I, diabetes. These patients must have injected insulin to stave off the long-term effects of improper glucose metabolism, which includes blindness, kidney disease, heart disease, nerve damage, limb loss and potentially death.
"After we confirmed that the baboon was indeed diabetic, we surgically placed the encapsulated islets into the animal's peritoneal cavity," said Dr. William Kendall Jr., senior surgical resident at Duke who prepared the results of the team's research for presentation Friday (June 15) at the bi-annual scientific meeting of the International Pancreas and Islet Transplant Association. The researchers also prepared a poster session on the novel baboon model they created for this study.
"To date, the animal's blood sugar levels have remained in the normal range, and it hasn't required any additional islet cell therapy," Kendall said. "We are very encouraged by these results."
Five more baboons are in various stages of study at Duke.
According to Emmanuel Opara, associate research professor of experimental surgery and cell biology at Duke University Medical Center, who began and leads Duke's islet cell transplant program, this approach promises a practically unlimited supply of islet cells that could put an end to the daily routine of multiple insulin injections for the more than 1 million Americans with Type I diabetes. Islet cell transplantation could also help approximately one-quarter of the 15 million Americans with Type II (adult onset) diabetes who require daily insulin injections.
A majority of people with Type II diabetes are not candidates for islet cell transplants, since the root of their disorder is not improper production of insulin, but rather the inability of receptors in the body to properly process insulin.
"We envision being able to place these islets within the abdomen of humans using existing laparoscopic, or minimally invasive, techniques," Opara said. "At this point we do not know how often patients with diabetes would need this therapy, but the baboon data to date are very encouraging. The first baboon is still diabetes-free after only the initial treatment." During the late 1990s, Opara's team developed the technique to envelope the islets within an alginate sphere. After isolating the insulin-producing islet cells from the rest of the pig pancreas tissue, they are bathed in the alginate solution and gently forced through a system that creates a protective sphere around each islet.
"The spheres have surface pores that are large enough to allow glucose to enter and insulin to exit, but are small enough to keep immune system cells from entering the spheres and attacking the islet cells," Opara said. "The spheres could be placed anywhere in the body where they come into contact with blood or other bodily fluids."
In the case of the first baboon, it required about 250,000 islets taken from about three pigs. While it is not yet known how many pig pancreases would be needed to yield enough islets for a human, there are more than 90 million pigs used for food production each year in the United States, more than enough needed to treat the number of Americans with diabetes, the researchers said.
Once the baboon became diabetic, its fasting glucose levels jumped from about 100 milligrams per decaliter of blood to about 400 mg/dL. During the nine-month period following the islet cell transplant, glucose levels averaged 115mg/dL. The researchers did not detect any signs that the baboon's immune system reacted to the pig islets.
The pancreas is a complex gland -- it not only regulates blood glucose levels, but also secretes enzymes that are crucial to digestion. This complexity has led to difficulties in developing a reliable animal model to study ways to treat the disease.
Some researchers have developed primate models of diabetes where the entire pancreas is removed, and while that does create the disease, it also causes significant digestive problems for the animal. Still other researchers have employed a chemical approach, using the compound streptozotocin, which is known to destroy the islet cells. However, since it injected systemically, streptozotocin causes complications to the animal's liver and kidneys. It is also an unreliable approach in baboons, if used alone.
The baboon model created by the Duke researchers is unique.
"We took an approach that employed the best of both earlier attempts, while avoiding the negative side effects of each," explained Kendall. "First, we removed about 90 percent of the pancreas, which left enough of the gland to maintain normal digestive functions. Then, we directly applied the streptozotocin to the remaining 10 percent of the pancreas during the operation – initially killing the majority of remaining islets cells while minimizing the systemic effects. We then administered additional small doses of streptozotocin systemically, as needed, to destroy any residual cells."
The researchers monitored an important biochemical marker to demonstrate that it was indeed the pig islets, and not some possibly surviving baboon islets, that were responsible for producing the insulin.
While in the pancreas, a precursor form of insulin (proinsulin) is attached to a peptide known as C-peptide. When this combined unit enters the bloodstream, it splits apart – the insulin goes about its business of regulating glucose levels, while the C-peptide travels through the liver to other tissues where it may help with other physiological activities.
"For instance, we know that C-peptide can protect the cardiovascular system from being damaged by the diabetes," Opara said. "Patients with diabetes inject purified insulin, not the complete proinsulin unit, and that is a reason why they must watch the long-term complications of the disease. They do not receive the C-peptide protection.
"In the baboon that received the islet cell transplant, we detected normal levels of porcine C-peptide, which indicates that porcine insulin was maintaining the proper glucose levels in the animal," Opara said. "The transplanted baboon also had much tighter blood glucose regulation than the control animal that was being treated with insulin injections alone."
Other Duke members of Opara's team include Drs. Brad Collins, Hasan Hobbs and Randy Bollinger. The islet cell research is supported by the Duke Department of Surgery and MicroIslet Inc., a San Diego-based firm that has licensed the rights of this technology from Duke. None of the Duke team members has a financial interest in MicroIslet.
Other social bookmarking and sharing tools:
The above story is reprinted from materials provided by Duke University Medical Center.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.